AbbVie Acquires Gilgamesh’s $1.2B Psychedelic Depression Therapy, Expanding Psychiatry Portfolio

North Chicago, IL and New York, August 25, 2025 (PRNewswire) -- AbbVie will acquire Gilgamesh Pharmaceuticals’ bretisilocin program for up to $1.2 billion, advancing a novel, short-acting psychedelic therapy currently in Phase 2 for major depressive disorder. The drug has demonstrated strong efficacy with a shorter psychoactive experience, addressing key limitations of existing psychedelic-based treatments. The acquisition strengthens AbbVie’s psychiatry pipeline while allowing Gilgamesh to spin out its remaining assets into a new company, Gilgamesh Pharma Inc.

Read full article here.